{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:37:48Z","timestamp":1772368668243,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T00:00:00Z","timestamp":1312848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold><jats:styled-content>Background<\/jats:styled-content>:<\/jats:bold> Restenosis after endovascular treatment for superficial femoral artery (SFA) disease remains a significant clinical issue. We assessed whether cilostazol reduce restenosis after SFA stenting with self\u2010expandable nitinol stent. <jats:bold><jats:styled-content>Methods<\/jats:styled-content>:<\/jats:bold> The study was a multicenter, prospective maintained database, retrospective analysis. From April 2004 to December 2009, 861 consecutive patients (mean age 71 years, 71% male) who underwent successful stenting for de novo lesions were retrospectively identified. Of them, 492 received cilostazol (cilostazol(+)) and 369 did not receive cilostazol (cilostazol(\u2212)) after procedure. Propensity\u2010score analyses matched 281 cilostazol(+) with 281 cilostazol (\u2212) group. Primary endpoint was binary restenosis rate. Secondary endpoints were reocclusion, all\u2010cause mortality and limb salvage in patients with critical limb ischemia (CLI). Restenosis was defined as &gt;2.4 of peak systolic velocity ratio by duplex. <jats:bold><jats:styled-content>Results<\/jats:styled-content>:<\/jats:bold> Mean follow\u2010up period was 25 months. According to analysis of matched pairs, binary restenosis rates were significantly lower (31.2% vs. 42.9% at 5\u2010year, <jats:italic>P<\/jats:italic> = 0.02). In\u2010stent re\u2010occlusion rate tended to be lower in patients who received cilostazol (10.8% vs. 18.2% at 5\u2010year, <jats:italic>P<\/jats:italic> = 0.09) compared with control. No significant difference of all\u2010cause mortality (21.4% vs. 18.3% at 5\u2010year, <jats:italic>P<\/jats:italic> = 0.84) and limb salvage rate in patients with CLI (86.2% vs. 78.5% at 5\u2010year, <jats:italic>P<\/jats:italic> = 0.29) was found between both groups. After adjustment for prespecified risk factors, cilostazol was an independent negative predictor of restenosis. In subgroup analysis, male, age &lt;75 years, claudicant patients, TASCII C\/D, small vessels and poor runoff vessel was significantly lower in binary restenosis. <jats:bold><jats:styled-content>Conclusions<\/jats:styled-content>:<\/jats:bold> Cilostazol reduced restenosis after SFA stenting with self\u2010expandable nitinol stent and it seems to be more effective in high\u2010risk patients for restenosis. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ccd.23304","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T15:33:32Z","timestamp":1311953612000},"page":"541-548","source":"Crossref","is-referenced-by-count":27,"title":["Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol"],"prefix":"10.1002","volume":"79","author":[{"given":"Yoshimitsu","family":"Soga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyohi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakiyo","family":"Nobuyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.109.903468"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2322031345"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.22128"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051303"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1583\/08-2461.1"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2004.02.039"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2009.01.035"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.11.054"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2006.09.024"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.688341"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.09.020"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.02.062"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2010.03.050"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0301-5629(92)90082-L"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.12.024"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.530097"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2009.08.040"},{"key":"e_1_2_6_19_2","first-page":"1144","article-title":"Effect of cilostazol on platelet aggregation and experimental thrombosis","volume":"35","author":"Kimura Y","year":"1985","journal-title":"Arzneimittelforschung\/Drug Res"},{"key":"e_1_2_6_20_2","first-page":"563","article-title":"Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo","volume":"37","author":"Ikeda Y","year":"1987","journal-title":"Arzneimittelforschung\/Drug Res"},{"key":"e_1_2_6_21_2","first-page":"1189","article-title":"Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease","volume":"35","author":"Yasunaga K","year":"1985","journal-title":"Arzneimittelforschung\/Drug Res"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806303182606"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.56.1.139"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2005.09.007"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000117403.64398.53"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.5551\/jat.10.93"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.01.007"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0003319710371619"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.23304","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.23304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T18:16:58Z","timestamp":1697480218000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.23304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,9]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1002\/ccd.23304"],"URL":"https:\/\/doi.org\/10.1002\/ccd.23304","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,9]]}}}